share_log

Avalo Therapeutics | ARS: Annual Report to Security Holders

Avalo Therapeutics | ARS: Annual Report to Security Holders

Avalo Therapeutics | ARS：年度报告
美股sec公告 ·  06/27 07:08
Moomoo AI 已提取核心信息
Avalo Therapeutics, a clinical-stage biotechnology company, reported a net loss of $31.5 million for the fiscal year ended December 31, 2023, with negative cash flows from operations amounting to $30.7 million. As of the end of the year, the company had $7.4 million in cash and cash equivalents. During the year, Avalo raised approximately $46.2 million through equity offerings and fully retired its $35 million debt. In March 2024, Avalo acquired AVTX-009, an anti-IL-1β monoclonal antibody, through the acquisition of AlmataBio Inc. Concurrently, Avalo closed a private placement financing for up to $185 million, with an initial investment of $115.6 million and potential additional proceeds of $69.4 million from warrant exercises. The funding is expected to support operations through the anticipated Phase 2 trial results of AVTX-009 in hidradenitis suppurativa in 2026 and into 2027. Avalo's common stock is listed on The Nasdaq Capital Market under the symbol 'AVTX'.
Avalo Therapeutics, a clinical-stage biotechnology company, reported a net loss of $31.5 million for the fiscal year ended December 31, 2023, with negative cash flows from operations amounting to $30.7 million. As of the end of the year, the company had $7.4 million in cash and cash equivalents. During the year, Avalo raised approximately $46.2 million through equity offerings and fully retired its $35 million debt. In March 2024, Avalo acquired AVTX-009, an anti-IL-1β monoclonal antibody, through the acquisition of AlmataBio Inc. Concurrently, Avalo closed a private placement financing for up to $185 million, with an initial investment of $115.6 million and potential additional proceeds of $69.4 million from warrant exercises. The funding is expected to support operations through the anticipated Phase 2 trial results of AVTX-009 in hidradenitis suppurativa in 2026 and into 2027. Avalo's common stock is listed on The Nasdaq Capital Market under the symbol 'AVTX'.
临床阶段的生物技术公司Avalo Therapeutics报告称，在2023年12月31日结束的财年中，净亏损3150万美元，运营现金流为负3070万美元。截至年底，公司持有现金及现金等价物740万美元。在该年度内，Avalo通过股票发行筹集了大约4620万美元，并完全还清了3500万美元的债务。2024年3月，Avalo通过收购AlmataBio Inc.收购了AVTX-009，一种抗IL-1β单克隆抗体。同时，Avalo进行了定向增发融资，最高可达1.85亿美元，初始投资为1.156亿美元，权证行使可能获得6940万美元的额外收益。该资金预计将支持到2026年肥厚性汗腺炎AVTX-009的二期试验结果，并持续到2027年。Avalo的普通股在纳斯达克资本市场上以‘AVTX’的标的物进行了上市。
临床阶段的生物技术公司Avalo Therapeutics报告称，在2023年12月31日结束的财年中，净亏损3150万美元，运营现金流为负3070万美元。截至年底，公司持有现金及现金等价物740万美元。在该年度内，Avalo通过股票发行筹集了大约4620万美元，并完全还清了3500万美元的债务。2024年3月，Avalo通过收购AlmataBio Inc.收购了AVTX-009，一种抗IL-1β单克隆抗体。同时，Avalo进行了定向增发融资，最高可达1.85亿美元，初始投资为1.156亿美元，权证行使可能获得6940万美元的额外收益。该资金预计将支持到2026年肥厚性汗腺炎AVTX-009的二期试验结果，并持续到2027年。Avalo的普通股在纳斯达克资本市场上以‘AVTX’的标的物进行了上市。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息